Hai Qian Selected Research

Guanosine Monophosphate (5' Guanylic Acid)

1/2018	The constitutively active PKG II mutant effectively inhibits gastric cancer development via a blockade of EGF/EGFR-associated signalling cascades.
10/2017	Type II cGMP‑dependent protein kinase inhibits the migration, invasion and proliferation of several types of human cancer cells.
7/2015	Nitric oxide/cyclic guanosine monophosphate inducers sodium nitroprusside and L-arginine inhibit the proliferation of gastric cancer cells via the activation of type II cyclic guanosine monophosphate-dependent protein kinase.
7/2015	Type II cyclic guanosine monophosphate-dependent protein kinase inhibits Rac1 activation in gastric cancer cells.
6/2015	Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hai Qian Research Topics

Disease

64	Neoplasms (Cancer) 11/2022 - 07/2011
20	Stomach Neoplasms (Stomach Cancer) 05/2022 - 01/2013
15	Type 2 Diabetes Mellitus (MODY) 01/2021 - 07/2011
12	Aneurysm (Aneurysms) 12/2020 - 06/2013
10	Body Weight (Weight, Body) 01/2021 - 01/2013
8	Hypoglycemia (Reactive Hypoglycemia) 10/2019 - 10/2015
7	Pain (Aches) 10/2021 - 05/2015
7	Diabetes Mellitus 01/2020 - 01/2015
5	Hyperthermia 04/2022 - 05/2015
5	Intracranial Aneurysm (Cerebral Aneurysm) 01/2022 - 01/2015
5	Breast Neoplasms (Breast Cancer) 01/2021 - 03/2020
5	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2016
4	Carcinogenesis 12/2019 - 07/2011
4	Infections 02/2016 - 12/2006
3	Inflammation (Inflammations) 01/2022 - 02/2012
3	Obesity 01/2021 - 09/2017
3	Lung Neoplasms (Lung Cancer) 12/2017 - 11/2012
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2017 - 11/2014
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 02/2012
2	Leukemia 01/2021 - 07/2011
2	Craniopharyngioma (Craniopharyngiomas) 01/2021 - 07/2011
2	Hypoxia (Hypoxemia) 10/2020 - 12/2019
2	Hemorrhage 01/2020 - 02/2019
2	Carcinoma (Carcinomatosis) 03/2018 - 04/2012
2	Pathologic Processes 01/2018 - 01/2018
2	Tetanus 06/2013 - 05/2012
1	Enteritis 01/2022

Drug/Important Bio-Agent (IBA)

21	Peptides (Polypeptides)IBA 02/2022 - 01/2015
18	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2012
14	Biological ProductsIBA 02/2022 - 07/2011
13	Pharmaceutical PreparationsIBA 01/2021 - 12/2006
10	Epidermal Growth Factor (EGF)IBA 11/2022 - 11/2012
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2017
10	Nonesterified Fatty Acids (NEFA)IBA 01/2020 - 01/2015
9	Protein Kinases (Protein Kinase)IBA 05/2022 - 04/2014
9	Complementary DNA (cDNA)IBA 10/2019 - 01/2013
8	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 05/2022 - 11/2012
8	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2021 - 01/2015
7	ErbB Receptors (EGF Receptor)IBA 11/2022 - 01/2013
7	Phosphotransferases (Kinase)IBA 10/2019 - 05/2013
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 08/2015
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2014
6	Analgesics (Analgesic Drugs)IBA 10/2021 - 05/2015
6	8-((4-chlorophenyl)thio)cyclic-3',5'-GMPIBA 07/2015 - 11/2012
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 11/2015
5	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2018 - 06/2015
4	Capsaicin (Zostrix)FDA Link 04/2022 - 02/2016
4	Adenosine Triphosphate (ATP)IBA 01/2021 - 01/2017
4	EnzymesIBA 01/2018 - 12/2013
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 05/2022 - 08/2016
3	AntigensIBA 01/2021 - 03/2020
3	serpentine (alkaloid)IBA 01/2020 - 04/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 11/2014
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 07/2015
3	Antineoplastic Agents (Antineoplastics)IBA 06/2019 - 01/2017
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 10/2018 - 01/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2018 - 01/2016
3	Arginine (L-Arginine)FDA Link 02/2018 - 07/2015
3	Cisplatin (Platino)FDA LinkGeneric 12/2017 - 10/2016
3	Antimicrobial PeptidesIBA 11/2017 - 07/2015
2	Becaplermin (PDGF-BB)FDA Link 05/2022 - 09/2018
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2022 - 11/2012
2	compound 20IBA 04/2022 - 09/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 02/2019
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2014
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2021 - 01/2017
2	IntegrinsIBA 12/2020 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 10/2020 - 12/2019
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 10/2020 - 03/2020
2	TetraspaninsIBA 01/2020 - 12/2019
2	Glucagon (Glukagon)FDA Link 01/2020 - 09/2017
2	LipidsIBA 01/2020 - 10/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 06/2019 - 01/2017
2	gluconic acid (gluconate)FDA LinkGeneric 05/2018 - 01/2017
2	cyclohexylaminoglutethimide (ChAG)IBA 03/2018 - 10/2016
2	Hyaluronic Acid (Hyaluronan)IBA 03/2018 - 10/2016
2	AcidsIBA 01/2018 - 07/2011
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 10/2017 - 10/2016
2	Matrix Metalloproteinases (MMPs)IBA 10/2017 - 10/2016
2	Blood Glucose (Blood Sugar)IBA 09/2017 - 08/2015
2	Indocyanine Green (Cardio-Green)FDA LinkGeneric 09/2017 - 07/2017
2	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 10/2016
2	Small Interfering RNA (siRNA)IBA 10/2016 - 10/2016
2	Serine (L-Serine)FDA Link 06/2016 - 07/2015
2	Tyrosine (L-Tyrosine)FDA Link 02/2016 - 07/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 11/2014
2	SodiumIBA 08/2015 - 06/2012
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2015 - 06/2015
2	LigandsIBA 05/2015 - 05/2013
2	Adrenergic Agents (Adrenergic Drugs)IBA 06/2013 - 05/2012
1	Threonine (L-Threonine)FDA Link 11/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022

Therapy/Procedure

21	Therapeutics 03/2021 - 11/2012
14	Drug Therapy (Chemotherapy) 04/2022 - 10/2011
4	Surgical Instruments (Clip) 09/2021 - 06/2013
3	Immunotherapy 01/2021 - 03/2020
3	Endovascular Procedures 12/2020 - 01/2015
2	Cerebral Revascularization 01/2022 - 02/2019
2	Craniotomy 07/2019 - 02/2019